Total Payments
$158,777
2024 Payments
$10,738
Companies
12
Transactions
113
Payment Breakdown by Category
Consulting$77,621 (48.9%)
Travel$36,423 (22.9%)
Other$31,493 (19.8%)
Education$5,605 (3.5%)
Research$4,841 (3.0%)
Food & Beverage$2,795 (1.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $77,621 | 29 | 48.9% |
| Travel and Lodging | $36,423 | 29 | 22.9% |
| Honoraria | $22,133 | 8 | 13.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,360 | 3 | 4.6% |
| Education | $5,605 | 1 | 3.5% |
| Unspecified | $4,841 | 3 | 3.0% |
| Food and Beverage | $2,795 | 39 | 1.8% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $2,000 | 1 | 1.3% |
Payments by Type
General
$153,936
110 transactions
Research
$4,841
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $60,170 | 35 | $0 (2022) |
| Chiesi USA, Inc. | $31,957 | 20 | $0 (2024) |
| APO-PHARMA INC. | $19,653 | 14 | $0 (2019) |
| Vifor (International) Ltd. | $17,464 | 9 | $0 (2021) |
| Agios Pharmaceuticals, Inc. | $15,330 | 22 | $0 (2024) |
| APO-PHARMA USA, INC. | $8,231 | 5 | $0 (2018) |
| Bio Products Laboratory USA, Inc. | $3,290 | 3 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $2,500 | 1 | $0 (2023) |
| Novo Nordisk Inc | $125.00 | 1 | $0 (2024) |
| Global Blood Therapeutics, Inc. | $23.51 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $10,738 | 7 | Chiesi USA, Inc. ($7,500) |
| 2023 | $11,085 | 4 | Chiesi USA, Inc. ($6,376) |
| 2022 | $19,947 | 16 | Celgene Corporation ($8,922) |
| 2021 | $14,714 | 9 | Celgene Corporation ($10,000) |
| 2020 | $15,093 | 17 | CHIESI USA, INC. ($7,584) |
| 2019 | $25,388 | 21 | Celgene Corporation ($14,525) |
| 2018 | $45,519 | 26 | Celgene Corporation ($20,973) |
| 2017 | $16,293 | 13 | APO-PHARMA INC. ($16,293) |
All Payment Transactions
113 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/07/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $3.66 | General |
| Category: Genetically Defined Disease | ||||||
| 12/06/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $125.00 | General |
| 08/07/2024 | Chiesi USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,499.91 | General |
| 08/07/2024 | Chiesi USA, Inc. | — | Travel and Lodging | Cash or cash equivalent | $3,000.00 | General |
| 04/18/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Honoraria | Cash or cash equivalent | $1,499.97 | General |
| Category: Genetically Defined Disease | ||||||
| 03/20/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Honoraria | Cash or cash equivalent | $1,499.97 | General |
| Category: Genetically Defined Disease | ||||||
| 03/19/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $109.76 | General |
| Category: Genetically Defined Disease | ||||||
| 12/09/2023 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $8.64 | General |
| Category: Genetically Defined Disease | ||||||
| 08/03/2023 | Chiesi USA, Inc. | FERRIPROX (Drug) | Honoraria | Cash or cash equivalent | $6,375.94 | General |
| Category: TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA | ||||||
| 01/25/2023 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Consulting Fee | Cash or cash equivalent | $2,200.00 | General |
| Category: Genetically Defined Disease | ||||||
| 01/18/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,499.95 | General |
| 12/10/2022 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $137.94 | General |
| Category: Genetically Defined Disease | ||||||
| 12/09/2022 | Celgene Corporation | REBLOZYL (Biological) | Travel and Lodging | Cash or cash equivalent | $1,236.00 | General |
| Category: Hematology | ||||||
| 12/09/2022 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Honoraria | Cash or cash equivalent | $1,100.00 | General |
| Category: Genetically Defined Disease | ||||||
| 12/09/2022 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $71.87 | General |
| Category: Genetically Defined Disease | ||||||
| 12/09/2022 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $60.00 | General |
| Category: Hematology | ||||||
| 12/09/2022 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $21.41 | General |
| Category: Hematology | ||||||
| 12/07/2022 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Consulting Fee | Cash or cash equivalent | $499.99 | General |
| Category: Genetically Defined Disease | ||||||
| 10/19/2022 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $56.06 | General |
| Category: Genetically Defined Disease | ||||||
| 08/17/2022 | Celgene Corporation | REBLOZYL (Biological) | Education | In-kind items and services | $5,604.60 | General |
| Category: Hematology | ||||||
| 05/20/2022 | Chiesi USA, Inc. | FERRIPROX (Drug) | Honoraria | Cash or cash equivalent | $3,498.96 | General |
| Category: HEMATOLOGY, DISEASE | ||||||
| 05/18/2022 | Chiesi USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $499.99 | General |
| 05/16/2022 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Honoraria | Cash or cash equivalent | $660.00 | General |
| Category: Genetically Defined Disease | ||||||
| 05/11/2022 | Chiesi USA, Inc. | FERRIPROX (Drug) | Consulting Fee | Cash or cash equivalent | $1,999.97 | General |
| Category: HEMATOLOGY, DISEASE | ||||||
| 05/11/2022 | Chiesi USA, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $999.98 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3, Double-Blind, Placebo Controlled Multicenter Study to Determine the Efficacy and Safety of Luspatercept (ACE-536) in Adults With Transfusion Dependent Beta (B)-Thalassemia (ACE-536-B-THAL-001) | Celgene Corporation | $3,432 | 2 |
| ACE-536-B-THAL-001 - A Phase 3, Double-Blind, Placebo Controlled Multicenter Study to Determine the Efficacy and Safety of Luspatercept (ACE-536) in Adults With Transfusion Dependent Beta (B)-Thalassemia | Celgene Corporation | $1,409 | 1 |
About Dr. Thomas Coates, MD
Dr. Thomas Coates, MD is a Pediatric Hematology-Oncology healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/22/2006. The National Provider Identifier (NPI) number assigned to this provider is 1790885697.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Coates, MD has received a total of $158,777 in payments from pharmaceutical and medical device companies, with $10,738 received in 2024. These payments were reported across 113 transactions from 12 companies. The most common payment nature is "Consulting Fee" ($77,621).
Ad
Practice Information
- Specialty Pediatric Hematology-Oncology
- Location Los Angeles, CA
- Active Since 09/22/2006
- Last Updated 01/10/2008
- Taxonomy Code 2080P0207X
- Entity Type Individual
- NPI Number 1790885697
Products in Payments
- Luspatercept (Drug) $24,000
- FERRIPROX (Drug) $22,567
- REBLOZYL (Biological) $21,672
- DEFERIPRONE (Drug) $14,543
- PYRUKYND (Drug) $7,848
- TIBSOVO (Drug) $7,482
- Reblozyl (Drug) $2,288
- DEFERIPRONE 80 MG/ML ORAL SOLUTION (Drug) $793.92
- Veltassa (Drug) $748.50
- OXBRYTA (Drug) $23.51
- ANDEXXA (Biological) $20.46
- GAMIFANT (Drug) $12.79
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Hematology-Oncology Doctors in Los Angeles
Jan Van Tornout, Md, MD
Pediatric Hematology-Oncology — Payments: $470,897
Pediatric Hematology-Oncology $470,897
Noah Federman, M.d, M.D
Pediatric Hematology-Oncology — Payments: $353,544
Pediatric Hematology-Oncology $353,544
Dr. Andrew Dietz, Md, Ms, MD, MS
Pediatric Hematology-Oncology — Payments: $88,475
Pediatric Hematology-Oncology $88,475
Mr. Paul Gaynon, M.d, M.D
Pediatric Hematology-Oncology — Payments: $65,183
Pediatric Hematology-Oncology $65,183
Edward Gomperts, Md, MD
Pediatric Hematology-Oncology — Payments: $65,090
Pediatric Hematology-Oncology $65,090
Dr. Geetha Puthenveetil, M.d, M.D
Pediatric Hematology-Oncology — Payments: $62,689
Pediatric Hematology-Oncology $62,689